CRIXIVAN Drug Patent Profile

When do Crixivan patents expire, and what generic alternatives are available?

Crixivan is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this compound. Additional details are available on the indinavir sulfate profile page.

Summary for CRIXIVAN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	11
Patent Applications:	4,606
Drug Prices:	Drug price information for CRIXIVAN
What excipients (inactive ingredients) are in CRIXIVAN?	CRIXIVAN excipients list
DailyMed Link:	CRIXIVAN at DailyMed

See drug prices for CRIXIVAN

Recent Clinical Trials for CRIXIVAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Oncology Institute of Southern Switzerland	Phase 2
Emory University	Phase 4
National Institutes of Health Clinical Center (CC)	Phase 1

See all CRIXIVAN clinical trials

US Patents and Regulatory Information for CRIXIVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-006	Apr 19, 2000		DISCN	No	No
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-001	Mar 13, 1996		DISCN	Yes	No
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-003	Mar 13, 1996		DISCN	Yes	No
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-005	Dec 17, 1998		DISCN	No	No

Expired US Patents for CRIXIVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-001	Mar 13, 1996	6,689,761
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-006	Apr 19, 2000	5,413,999
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-001	Mar 13, 1996	5,413,999
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-003	Mar 13, 1996	6,689,761
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-005	Dec 17, 1998	6,689,761

International Patents for CRIXIVAN

See the table below for patents covering CRIXIVAN around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2112880
Malaysia	121604	COMBINATION THERAPY FOR HIV INFECTION USING THE HIV PROTEASE INHIBITOR INDINAVIR AND THE REVERSE TRANSCRIPTASE INHIBITOR 3TC TOGETHER WITH AZT
Slovenia	9420017	HIV PROTEASE INHIBITORS IN PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF AIDS
Russian Federation	2139052	КОМБИНАЦИЯ ИНГИБИТОРА ВИЧ-ПРОТЕАЗЫ С ДРУГИМИ АНТИВИРУСНЫМИ СОЕДИНЕНИЯМИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ПОЛУЧЕНИЯ ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ (COMBINATION OF HIV-PROTEASE INHIBITOR WITH OTHER ANTIVIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITION BASED ON SAID AND METHOD OF PHARMACEUTICAL COMPOSITION PREPARING)
Slovakia	136395	HIV PROTEASE INHIBITORS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM

CRIXIVAN: Patent Expiry, Market Dynamics, and Generics Landscape

Last updated: February 19, 2026

Executive Summary

Crixivan (indinavir sulfate), an HIV protease inhibitor developed by Merck & Co., Inc., is nearing patent expiry, signaling a significant shift in its market landscape. The drug's exclusivity period has largely concluded, allowing for the introduction and market penetration of generic versions. This transition is expected to lead to substantial price erosion, increased patient access, and a redefinition of Merck's revenue streams from this therapeutic area. The efficacy of CRIXIVAN in combination therapy, particularly in the early era of HIV treatment, has been established, but newer agents with improved tolerability and resistance profiles have since emerged. This analysis outlines the patent status, market performance, and competitive environment for CRIXIVAN, providing a data-driven outlook for stakeholders.

What is CRIXIVAN and Its Therapeutic Significance?

CRIXIVAN (indinavir sulfate) is an oral antiretroviral medication belonging to the class of protease inhibitors. It functions by blocking the activity of HIV protease, an enzyme essential for the virus's replication cycle. By inhibiting this enzyme, CRIXIVAN prevents the maturation of newly formed virus particles, thereby reducing viral load in the body.

The drug was initially approved by the U.S. Food and Drug Administration (FDA) in 1996, marking a critical advancement in the treatment of Human Immunodeficiency Virus (HIV) infection. Its introduction was a pivotal moment, contributing to the development of highly active antiretroviral therapy (HAART), a combination approach that significantly improved patient outcomes and transformed HIV from a rapidly fatal disease into a manageable chronic condition. The clinical significance of CRIXIVAN lies in its ability to lower viral RNA levels, increase CD4+ cell counts, and reduce the risk of opportunistic infections and mortality in HIV-positive individuals.

What is the Patent Status of CRIXIVAN?

The primary patent for CRIXIVAN, U.S. Patent No. 5,413,999, covering the compound indinavir, was filed on June 22, 1993, and granted on May 7, 1996. This patent provided market exclusivity for a period of 20 years from the filing date. Therefore, the original compound patent protection for indinavir expired on June 22, 2013.

While the core compound patent has expired, Merck may have held other related patents, such as those covering specific formulations, manufacturing processes, or methods of use. However, these secondary patents typically do not extend market exclusivity for the active pharmaceutical ingredient itself to the same extent as the compound patent.

The expiration of the primary patent has opened the door for generic manufacturers to seek FDA approval and market their own versions of indinavir sulfate. This process typically involves submitting an Abbreviated New Drug Application (ANDA), demonstrating bioequivalence to the reference listed drug, CRIXIVAN.

How Has CRIXIVAN Performed Financially?

CRIXIVAN was a significant revenue driver for Merck during its peak years of market exclusivity. Introduced in 1996, its sales rapidly climbed, reflecting its crucial role in the burgeoning HAART regimens.

• Peak Sales: CRIXIVAN achieved peak annual sales of approximately $1.6 billion in the late 1990s and early 2000s. This performance was driven by its efficacy and its status as a foundational component of HIV treatment protocols.
• Sales Decline Post-Exclusivity: Following the expiration of its primary patent and the subsequent introduction of generic competition, CRIXIVAN's sales experienced a sharp decline. This decline is a typical market dynamic for branded pharmaceuticals as lower-cost generic alternatives become available.
• Recent Revenue Contribution: In recent years, CRIXIVAN's contribution to Merck's overall revenue has become marginal. For instance, in the fiscal year 2022, CRIXIVAN sales were reported to be less than $10 million globally, a stark contrast to its historical performance. This minimal revenue reflects its diminished market share and the availability of newer, more advanced HIV therapies.

What is the Current Market Landscape for CRIXIVAN?

The current market for CRIXIVAN is characterized by a mature product status, significantly impacted by the availability of generic indinavir sulfate.

• Generic Competition: Multiple generic manufacturers have successfully entered the market with indinavir sulfate, offering substantially lower prices compared to the original branded product. This competition has fragmented the market and driven down overall sales volume for the innovator drug.
• Therapeutic Evolution: The HIV treatment landscape has evolved considerably since CRIXIVAN's introduction. Newer antiretroviral drugs, including integrase inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs), have demonstrated superior efficacy, improved safety profiles, enhanced tolerability, and simplified dosing regimens. These advancements have led to a shift in prescribing patterns, with many clinicians opting for newer agents over older ones like CRIXIVAN, even in generic form.
• Patient Access and Cost: The availability of generic indinavir sulfate has undoubtedly improved patient access, particularly in resource-limited settings, by making the treatment more affordable. However, its usage is now often limited to specific patient populations or treatment regimens where it remains clinically appropriate and cost-effective, or where patients have developed resistance to newer agents.
• Geographic Variations: Market penetration and usage of generic indinavir may vary by region, influenced by local healthcare policies, pricing regulations, and the availability of alternative treatments.

Who are the Key Generic Competitors?

The generic market for indinavir sulfate includes several pharmaceutical companies that have successfully obtained FDA approval to market their versions. These companies focus on manufacturing and distributing cost-effective alternatives. Key generic players include:

• Teva Pharmaceuticals: A major global pharmaceutical company with a broad portfolio of generic drugs.
• Mylan N.V. (now Viatris): Another significant player in the generic pharmaceutical market, known for its extensive range of off-patent medicines.
• Sun Pharmaceutical Industries Ltd.: An Indian multinational pharmaceutical company that is a prominent supplier of generic drugs worldwide.
• Aurobindo Pharma Limited: An Indian pharmaceutical company with a strong presence in the generic API and finished dosage forms market.

These companies, among others, contribute to the competitive pricing and broad availability of indinavir sulfate globally. Their ability to manufacture indinavir sulfate efficiently and navigate regulatory pathways allows them to capture market share post-patent expiry.

What is the Future Outlook for CRIXIVAN?

The future outlook for CRIXIVAN, both branded and generic, is characterized by continued decline in demand and a significantly reduced market presence.

• Declining Prescription Volume: As newer, more convenient, and better-tolerated HIV therapies continue to be developed and adopted, the prescription volume for indinavir sulfate is expected to decrease further. The trend in HIV treatment is towards single-tablet regimens and drugs with fewer side effects, making older drugs like indinavir sulfate less attractive.
• Niche Applications: Generic indinavir may persist in niche applications, such as for patients with specific treatment histories, drug resistance patterns, or in regions with severe cost constraints where it remains a viable option within a broader public health strategy.
• Merck's Strategic Focus: Merck has shifted its strategic focus to newer HIV treatment modalities, including integrase inhibitors and long-acting injectables, which represent the cutting edge of HIV therapy. Revenue from legacy products like CRIXIVAN is unlikely to be a significant factor in the company's future financial trajectory.
• Market Saturation: The generic market for indinavir sulfate is likely to remain saturated, with continued price competition among manufacturers, leading to persistent low pricing. Profitability for generic manufacturers will depend on efficient production and distribution networks.

Key Takeaways

• CRIXIVAN's primary compound patent expired in June 2013, enabling generic market entry.
• Peak annual sales for branded CRIXIVAN approached $1.6 billion, but recent global sales are below $10 million.
• The market is now dominated by generic indinavir sulfate, offered by companies including Teva, Viatris, and Sun Pharma.
• Advancements in HIV therapeutics have led to newer agents with superior profiles, reducing CRIXIVAN's clinical relevance.
• The future outlook for CRIXIVAN involves continued declining prescription volumes and a marginal market presence, primarily in niche applications.

Frequently Asked Questions

1. When was CRIXIVAN first approved by the FDA? CRIXIVAN was first approved by the U.S. Food and Drug Administration (FDA) in 1996.

2. What is the mechanism of action for CRIXIVAN? CRIXIVAN is a protease inhibitor that blocks the activity of HIV protease, an enzyme necessary for viral replication.

3. Has Merck discontinued the branded version of CRIXIVAN? While Merck's revenue contribution from CRIXIVAN is minimal, the branded product may still be available, though its market share is overshadowed by generics. Specific product discontinuation status would require direct confirmation from Merck.

4. What are the main reasons for the decline in CRIXIVAN usage? The decline is attributed to the expiration of patents and the introduction of generic versions, alongside the development of newer HIV medications with improved efficacy, tolerability, and simpler dosing regimens.

5. Are there any remaining patent protections for CRIXIVAN? The primary compound patent has expired. While secondary patents covering specific formulations or processes may have existed, they typically do not grant the same level of market exclusivity as the compound patent for the active ingredient.

Citations

[1] U.S. Patent No. 5,413,999. (1996). United States Patent Office. [2] Merck & Co., Inc. (2023). Form 10-K Annual Report for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission. [3] Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [FDA website] [4] Various Generic Pharmaceutical Company Websites and Product Information. (Accessed 2023). [5] Clinical Guidelines and HIV Treatment Protocols from Reputable Medical Organizations. (Ongoing).